Latest Alzheimer's Drug Discovery Foundation Stories
Glia-based approach to Alzheimer's disease provides a novel opportunity for treatment NEW YORK, March 17, 2015 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation
Glia-based approach to Alzheimer's disease provides a novel opportunity for treatment BOSTON, March 17, 2015 /PRNewswire-USNewswire/ -- GliaCure, a biotechnology company developing
NEW YORK, March 3, 2015 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City
Cross-Sector Collaboration Aims to Provide Academic Researchers with New Investments and Access to Pfizer's Scientific Expertise and Resource Centers NEW YORK, Feb.
AGB101 could be the first drug to modify progression of amnestic mild cognitive impairment (aMCI) in patients at a high-risk for progressing to Alzheimer's dementia NEW YORK, Jan.
Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer's Disease BALTIMORE, Jan.
NEW YORK and MILAN, Italy, Dec.
New Funding From US and UK Will Facilitate "Clinical Test of Concept" NEW YORK, Dec.
NEW YORK, Sept.
Paper Addresses Challenges and Explores Opportunities to Stimulate Repurposing of FDA-Approved Drugs for Alzheimer's, Parkinson's and Related Diseases NEW YORK, June 26, 2014 /PRNewswire-USNewswire/
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.